Evidence map›Paper›PMID 42539055›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Comprehensive molecular characterization of cutaneous squamous cell carcinoma reveals determinants of metastatic progression.

Barbara Rentroia-Pacheco, Harsh Sharma, Lara Pozza, Joleen J H Traets, Bishal Tandukar, Olivia F M Steijlen, Romy Ruiter, Noel Cruz-Pacheco, Daphne Huigh, Arne Van Hoeck and 13 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Barbara Rentroia-PachecoErasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Dermatology, Rotterdam, the Netherlands.ORCID 0000-0003-0073-4269
Harsh SharmaDepartment of Dermatology, University of California San Francisco, USA.ORCID 0000-0002-9862-6794
Lara PozzaSkylineDx B.V., Rotterdam, The Netherlands.ORCID 0009-0000-8834-8121
Joleen J H TraetsSkylineDx B.V., Rotterdam, The Netherlands.ORCID 0000-0003-0505-9776
Bishal TandukarDepartment of Dermatology, University of California San Francisco, USA.ORCID 0000-0002-9650-1664
Olivia F M SteijlenErasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Dermatology, Rotterdam, the Netherlands.ORCID 0000-0002-9183-9287
Romy RuiterSkylineDx B.V., Rotterdam, The Netherlands.ORCID 0009-0003-9659-4682
Noel Cruz-PachecoDepartment of Dermatology, University of California San Francisco, USA.ORCID 0000-0001-8989-7093
Daphne HuighSkylineDx B.V., Rotterdam, The Netherlands.
Arne Van HoeckErasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Dermatology, Rotterdam, the Netherlands.ORCID 0000-0002-6570-1452
Yan-Ting ChenSkylineDx B.V., Rotterdam, The Netherlands.ORCID 0000-0002-5273-3914
Beatriz InfanteSkylineDx B.V., Rotterdam, The Netherlands.ORCID 0009-0009-6547-3873
Defne BaskurtDepartment of Dermatology, University of California San Francisco, USA.ORCID 0000-0002-9923-205X
Vignesh ArunachalamDepartment of Dermatology, University of California San Francisco, USA.ORCID 0000-0003-1228-7064
Celeste J EggermontErasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Dermatology, Rotterdam, the Netherlands.ORCID 0000-0002-1669-0283
Amanda Bas-Cristóbal MenéndezSkylineDx B.V., Rotterdam, The Netherlands.ORCID 0000-0002-6854-3269
Tamar NijstenErasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Dermatology, Rotterdam, the Netherlands.ORCID 0000-0001-9940-2875
Harmen J G van de WerkenErasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Immunology, Rotterdam, The Netherlands.ORCID 0000-0002-9794-1477
Antien L MooyaartErasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Pathology, Rotterdam, The Netherlands.ORCID 0000-0001-9810-5780
Domenico BellomoSkylineDx B.V., Rotterdam, The Netherlands.ORCID 0000-0003-2289-5944
Marlies WakkeeErasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Dermatology, Rotterdam, the Netherlands.ORCID 0000-0001-8578-901X
A Hunter ShainDepartment of Dermatology, University of California San Francisco, USA.ORCID 0000-0002-2999-9706
Loes M HollesteinErasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Dermatology, Rotterdam, the Netherlands.ORCID 0000-0001-8922-6791

Funding

Pre-cancer atlas of skin cancerU01CA294536 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BASTIAN, BORIS C., SHAIN, ALAN HUNTER · 2024 to 2025
$5.2M
The genomic landscape and evolution of cutaneous squamous cell carcinomaR01CA265786 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Hunter Shain · 2022 to 2026
$2.1M
The mutational mechanisms shaping melanocytes in human skinR01AR080626 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Hunter Shain · 2023 to 2026
$1.6M
NCI NIH HHS R01 CA265786NCI NIH HHS U01 CA294536NIAMS NIH HHS R01 AR080626
6 · The paper itself

Abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of cancer worldwide. While most cSCCs are not life-threatening, 2-5% of patients develop metastases. To better understand what causes some cSCCs to progress to metastatic disease, we assembled a nationwide cohort of 19,120 patients with clinico-pathologically annotated tumors linked to metastatic outcome. RNA-sequencing was performed on 378 tumors, and whole-exome sequencing on 147, with balanced numbers of tumors that progressed to metastatic disease (cases) and did not (controls). UV radiation was the dominant mutational signature with additional contributions from aging, APOBEC activity, and, in immunosuppressed patients, azathioprine exposure. We identified 38 genes under selection across a core set of signaling pathways. Gene expression clusters were primarily associated with the differentiation state of tumor cells and secondarily with the composition of the tumor microenvironment. Several mutational and transcriptional programs were associated with metastasis, including a dedifferentiated gene expression signature, activating mutations in the RAS signaling pathway, loss-of-function alterations in the SWI/SNF chromatin remodeling complex, and specific arm-level copy number alterations. A 23-gene expression signature was built to predict metastasis from primary cSCC tissue. The signature was validated in two independent cohorts (N=102 and 52), where it predicted metastasis independently of staging systems. Together, these findings provide the most detailed molecular portrait of cSCC to date and establish an assay for risk stratification suitable for clinical implementation.

Identifiers

PMID42539055
PMCPMC13419656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.